Print

Nanosphere, Inc.'s Verisens(TM) Ultra-Sensitive PSA Assay Combined With the AnalizaDx SIA Technology Shows Promising Results for Improved Prostate Cancer Diagnosis  
10/7/2010 9:44:32 AM

NORTHBROOK, Ill. and CLEVELAND, Oct. 7, 2010 (GLOBE NEWSWIRE) -- At the annual meeting of the North-Central American Urological Association, Mark Stovsky, MD, Case Western Reserve University School of Medicine – Case Medical Center, and principal investigator, presented positive data combining the AnalizaDx SIA technology with the Nanosphere Verisens™ ultra-sensitive PSA assay (research use only). Nanosphere is collaborating with AnalizaDx – which has developed a proprietary platform to screen for protein biomarkers in serum and other biological fluids – on development of next-generation PSA tests for prostate cancer.
//-->